VLX 600

Drug Profile

VLX 600

Alternative Names: VLX600

Latest Information Update: 18 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Karolinska Institute; Vivolux
  • Developer Vivolux
  • Class Cytostatics; Indoles; Methylhydrazines; Pyridines; Small molecules
  • Mechanism of Action Iron chelating agents; Mitochondrial protein inhibitors; UCHL5 protein inhibitors; USP14 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 18 May 2016 Chemical information added
  • 17 May 2016 Phase-I development is ongoing in USA
  • 01 Sep 2014 Phase-I clinical trials in Solid tumours (Refractory metastatic disease) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top